New target for antidepressants revealed
June 1st, 2010 - 2:13 pm ICT by ANIWashington, June 1 (ANI): Researchers at University of Michigan have provided the most detailed picture yet of a key receptor in the brain that influences the effectiveness of serotonin-related antidepressants, such as Prozac.The finding paves the way for a more targeted treatment of depression and anxiety with fewer side effects.
Depressive disorders change a person’s mood, emotions and physical well-being and can co-occur with anxiety disorders and substance abuse.
“There are big drawbacks in the current therapies for depression. Therapeutic benefits are delayed, there are unwanted side effects, and it’s not unusual for depressive symptoms to return,” said senior author Dr. John Traynor, professor of pharmacology at the U-M Medical School and director of the U-M Substance Abuse Research Center.
The best current treatments for depression are selective serotonin reuptake inhibitors, or SSRIs. These drugs work by flooding the brain’s synapses with serotonin, a neurotransmitter linked with mood, and increasing signalling through the more than 20 serotonin receptors in the brain.
However the team of researchers showed that one particular pathway, the serotonin 5HT1a receptor is linked with antidepressive and anti-anxiety behaviour in mice.
“Rather than activating all serotonin receptors as SSRIs do, one could increase signaling through the one critical serotonin receptor that our research shows is important for anti-depressant behavior,” said co-author Dr. Richard R. Neubig.
The study details the complex actions of a family of proteins, known as RGS proteins that act as brakes on neurotransmitter signaling.
Researchers created a mutant mouse to boost serotonin signalling at the 5HT1a receptor.
This was done by genetically inhibiting the activity of braking proteins.
Without the normal brake on serotonin signalling, these mutant mice showed antidepressive behaviour even without being given antidepressant drugs.
The mice were also more responsive to SSRIs.
According to the authors, further research could lead to drugs capable of inhibiting the RGS proteins and which would target the antidepressant signal where it is required on critical 5HT1a receptors.
The study appears in the journal Proceedings of the National Academy of Sciences. (ANI)
- New mouse model to probe how antidepressants work - Feb 19, 2011
- Genetically defective mice to help understand human depression - Jun 30, 2010
- Delating a gene works up smarter brain - Mar 11, 2012
- Gene therapy to brain may treat major depression - Oct 21, 2010
- Anti cholesterol drug causes depression: Indian scientists - Jun 23, 2010
- Blood test to tell whether anti-depressants work - Dec 16, 2011
- Anti-depressants doing more harm than good: Study - Apr 25, 2012
- Serotonin research could lead to new therapies for schizophrenia - Oct 06, 2010
- Why antidepressants often fail - Jan 14, 2010
- Mice study finds link between depression and inflammatory response - Dec 21, 2010
- How anti-depressants create brain cell - Apr 13, 2011
- 'Gene fix' to treat depression - Oct 22, 2010
- Neurological protein may hold the key to novel depression treatments - Nov 30, 2010
- Recovery Of Patients From A Stroke Could Be Assisted By Multiuse Drugs Such As Prozac - Jan 11, 2011
- Antidepressant use linked to thicker arteries - Apr 03, 2011
Tags: anxiety disorders, current treatments for depression, depressive disorders, drugs work, john traynor, m medical school, mutant mice, mutant mouse, rgs proteins, selective serotonin reuptake inhibitors, serotonin receptor, serotonin receptors, serotonin reuptake inhibitors, study details, substance abuse research, substance abuse research center, target, therapeutic benefits, treatment of depression, treatments for depression